[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [BUSINESS]

2 clusters · 4 sources · 3 days · First seen · Last updated

AI biotechnology funding and development

Overview

Aureka Biotechnologies has secured $100 million in Series B financing, bringing its total funding to nearly $200 million. The funding round was structured in tranches, with Granite Asia exclusively funding the first tranche, followed by a subsequent tranche led by a strategic investor with participation from HighLight Capital and existing shareholders MPCi and NRL Capital.

The company plans to use the proceeds to research and train next-generation biological foundation models for tasks such as de novo molecular design, biological structure modeling, and function prediction. Aureka also intends to upgrade its ‘Lab-in-the-Loop’ platform, which integrates AI models with single-cell functional screening and high-throughput experimental validation to facilitate a continuous feedback loop for drug development.

Entities

Caltech · Aizen Therapeutics · Aureka Biotechnologies · Granite Asia

Timeline

  1. 13 days ago

    [BUSINESS] 2 sources
    AI biotechnology firms secure major funding and partnerships

    AI-driven biotech firms Aizen Therapeutics and Aureka Biotechnologies are advancing drug discovery through new collaborations and significant funding rounds totaling hundreds of millions of dollars.

  2. 16 days ago

    [BUSINESS] 3 sources
    Aureka Biotechnologies raises $100 million in Series B funding

    Aureka Biotechnologies raised $100 million in Series B funding to develop biological foundation models and AI-driven drug discovery infrastructure, bringing its total funding to nearly $200 million.

Sources

aijourn.com · mindef.gov.sg · pulse2.com · startupdaily.net